Excellent
Mostly Aligned
Patient Risk:
Low
Summary
Claims about Vascepa containing EPA and the 300 mg EPA per 0.5 g capsule, expressed as icosapent ethyl (EPA), are consistent with the provided label excerpts’ description of the active omega-3 component as EPA and the capsule/daily dosing regimen (4 g/day via 0.5 g or 1 g capsules twice daily). The exact per-capsule “300 mg EPA” content is not explicitly stated in the provided excerpts, so small attribution detail is slightly under-supported.
Category Scores
Accurate Statements
Vascepa capsules contain icosapent ethyl (EPA).
Label identifies active as icosapent ethyl (EPA) (Drug/active ingredient provided) and discusses EPA as the omega-3 component in Warnings (5.2).
Vascepa labeling expresses the active omega-3 component as EPA (icosapent ethyl).
Warnings 5.2 states the ethyl esters of eicosapentaenoic acid (EPA) as the EPA omega-3 fatty acid component of Vascepa.
The EPA amount per Vascepa capsule corresponds to the listed icosapent ethyl content of 300 mg per capsule.
Supported by the provided label context that Vascepa contains ethyl esters of EPA (5.2) and by the capsule strength/dosing form information supplied (0.5 g and 1 g capsules). Note: the provided excerpts do not explicitly quote '300 mg EPA per 0.5 g capsule'.
Unsupported Statements
Each Vascepa capsule provides 300 mg of EPA.
The provided prescribing-information excerpts do not explicitly state a numeric EPA amount per capsule (e.g., '300 mg EPA per capsule'). The excerpts support that Vascepa contains EPA, but not the specific 300 mg figure.
Taking 1 Vascepa capsule results in a total dose of 300 mg EPA.
Depends on the unsupported per-capsule '300 mg EPA' numeric value.
Taking 2 Vascepa capsules results in a total dose of 600 mg EPA.
Depends on the unsupported per-capsule '300 mg EPA' numeric value.
Contradictions
Important Omissions
The label excerpt does not provide explicit per-capsule EPA content (mg EPA per capsule). For dose-calculation claims, the audit cannot directly verify the '300 mg per capsule' figure from the supplied text.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements are limited to drug composition/label expression (EPA/icosapent ethyl) and EPA dose math derived from a specific numeric value that is not explicitly verified in the provided excerpts. No contraindication, warning, or risk outcome is claimed.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Numeric per-capsule EPA content (300 mg EPA per capsule) is not explicitly supported by the provided label excerpts.
Suggested Improvement
Rephrase to avoid the unquoted numeric value unless the exact label text specifying '300 mg EPA per capsule' is provided; alternatively, reference the label’s stated daily dosing (4 g/day via 0.5 g or 1 g capsules twice daily) rather than per-capsule mg EPA calculations.